Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On March8, 2017, the Board of Directors of Proteostasis
Therapeutics, Inc., or the Company, elected Brett Hagen, the
Companys Vice President of Finance, Controller, Assistant
Treasurer and Principal Accounting Officer, to the additional
position of Principal Financial Officer. The Company announced
this election on the date hereof, by press release.
Mr.Hagen, age 43, has been serving as the Companys Controller
since May 2016, Principal Accounting Officer since August 2016,
Assistant Treasurer since October 2016, Vice President of Finance
since February 2017, and Principal Financial Officer since March
2017.Previously, Mr.Hagen served as the controller for BIND
Therapeutics, Inc. (NASDAQ: BIND), Vice President,
Finance/Segment Controller of Boston Private Financial Holdings
(NASDAQ: BPFH), Manager of SEC Financial Reporting and Technical
Account of The Princeton Review, Controller of BioProcessors
Corporation and held a number of positions at
PricewaterhouseCoopers LLP. He received a B.A. from the
University of Minnesota, a Master in Accountancy from Wright
State University and a M.S. in Finance from Suffolk University.
| Item7.01 | Regulation FD Disclosure. |
On March30, 2017, the Company issued a press release announcing
its financial results for the quarter and fiscal year ended
December31, 2016, and corporate updates. A copy of the press
release is furnished hereto as Exhibit 99.1.
Spokespersons of the Company plan to present the information in
the presentation slides furnished hereto as Exhibit 99.2.
The furnishing of the attached presentation slides is not an
admission as to the materiality of any information therein. The
information contained in the slides is summary information that
is intended to be considered in the context of more complete
information included in the Companys filings with the SEC and
other public announcements that the Company has made and may make
from time to time by press release or otherwise. The Company
undertakes no duty or obligation to update or revise the
information contained in this report, although it may do so from
time to time as its management believes is appropriate. Any such
updating may be made through the filing of other reports or
documents with the SEC, through press releases or through other
public disclosures. For important information about forward
looking statements, see the slide titled Safe Harbor and
Disclaimer in Exhibit 99.2 attached hereto.
The information in this Item 7.01 of this Current Report on Form
8-K and Exhibits
99.1 and 99.2 attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained in this Item 7.01 and in the
press release attached as Exhibit 99.1 and the presentation
slides attached as Exhibit 99.2 to this Current Report shall not
be incorporated by reference into any filing with the SEC made by
the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such
filing.
| Item9.01 | Financial Statements and Exhibits. |
(d)
Exhibits
|
Exhibit No. |
Description |
|
| 99.1 | Press release dated March 30, 2017, furnished herewith | |
| 99.2 | Presentation slides, furnished herewith |
About Proteostasis Therapeutics, Inc. (NASDAQ:PTI)
Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Recent Trading Information
Proteostasis Therapeutics, Inc. (NASDAQ:PTI) closed its last trading session down -0.21 at 10.89 with 56,889 shares trading hands.